Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006–2010

PLoS One
[Accessed 21 September 2013]

Research Article
Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006–2010
Catherine A. Panozzo, Sylvia Becker-Dreps, Virginia Pate, Michele Jonsson Funk, Til Stürmer,
David J. Weber, M. Alan Brookhart

Rotavirus vaccines are highly effective at preventing gastroenteritis in young children and are now universally recommended for infants in the US. We studied patterns of use of rotavirus vaccines among US infants with commercial insurance. We identified a large cohort of infants in the MarketScan Research Databases, 2006–2010. The analysis was restricted to infants residing in states without state-funded rotavirus vaccination programs. We computed summary statistics and used multivariable regression to assess the association between patient-, provider-, and ecologic-level variables of rotavirus vaccine receipt and series completion. Approximately 69% of 594,117 eligible infants received at least one dose of rotavirus vaccine from 2006–2010. Most infants received the rotavirus vaccines at the recommended ages, but more infants completed the series for monovalent rotavirus vaccine than pentavalent rotavirus vaccine or a mix of the vaccines (87% versus 79% versus 73%, P<0.001). In multivariable analyses, the strongest predictors of rotavirus vaccine series initiation and completion were receipt of the diphtheria, tetanus and acellular pertussis vaccine (Initiation: RR=7.91, 95% CI= 7.69–8.13; Completion: RR=1.26, 95% CI=1.23–1.29), visiting a pediatrician versus family physician (Initiation: RR=1.51, 95% CI=1.49–1.52; Completion: RR=1.13, 95% CI=1.11–1.14), and living in a large metropolitan versus smaller metropolitan, urban, or rural area. We observed rapid diffusion of the rotavirus vaccine in routine practice; however, approximately one-fifth of infants did not receive at least one dose of vaccine as recently as 2010. Interventions to increase rotavirus vaccine coverage should consider targeting family physicians and encouraging completion of the vaccine series.